Full Text
PCN63 The Relative Value of Dasatinib Versus Imatinib as First-Line Treatment for Chronic Myeloid Leukemia

Abstract

Authors

L. Betegon I. Gilloteau P. Martin A. Woolmore I. Oyagüez

Back to Volume 15, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×